Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.

@article{Cioppa2012SuperiorIO,
  title={Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.},
  author={Giovanni Della Cioppa and Uwe Nicolay and Kelly Lindert and Geert Leroux-Roels and Fr{\'e}d{\'e}ric Cl{\'e}ment and Flora Castellino and Grazia Galli and Nicola Groth and Giuseppe Del Giudice},
  journal={Human vaccines & immunotherapeutics},
  year={2012},
  volume={8 2},
  pages={216-27}
}
BACKGROUND MF59-adjuvanted influenza vaccines have superior immunogenicity in older adults compared with non-adjuvanted vaccines. We assessed whether changing formulation (i.e., increasing H3N2 antigen or decreasing the quantity of adjuvant) of the licensed, MF59-adjuvanted trivalent influenza subunit vaccine Fluad (®) (Novartis Vaccines and Diagnostics… CONTINUE READING